Cardiology

With hypertension commonly leading to increased risk of mortality, researchers aimed to understand the hypertensive survival rates of patients with diabetes over a 20-year period.

A real-world study found that semaglutide significantly reduced the risk of major cardiovascular events compared to tirzepatide.

Using results from the Rx for Change program in Pittsburgh, Pennsylvania, researchers explored an integrative approach to cardiometabolic disease management among Black patients.

However, caution with empagliflozin use should be applied for patients previously taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

Investigators find this association primarily affects female patients when compared with male patients.

The FDA removes the prior requirement for a patient who is already diagnosed with a cardiovascular disease.

Investigators found that health care costs rose despite the benefits seen with starting semaglutide for patients with and without diabetes.

Although stroke is not common in pregnancy or childbearing years, pregnancy can increase the risk.

In an exploration of recent mothers across the US, researchers addressed the association of hypertensive disorders during pregnancy with breastfeeding and breastfeeding cessation.

After the certification of a new stroke center in respective communities, researchers compared the stroke outcomes of Black patients with those of White patients.

In the study, tirzepatide (Mounjaro) improved measures of A1c, weight, renal function, and all-cause mortality.

The updated label removes the requirement that inclisiran should be used on top of or in combination with statin therapies.

The 2 corporations formed the Bristol Myers Squibb-Pfizer Alliance and will be offering discounted Eliquis to eligible patients starting September 8, 2025.

Seven major clinical trials reveal semaglutide’s expanding benefits beyond glucose control, showing promise in kidney, heart, liver, vascular, and obesity-related outcomes.

Researchers investigated the timing of hypertension diagnosis, exploring its association with medication prescribing and long-term cardiovascular outcomes.

The approval is based on the FINEARTS-HF (NCT04435626), showing that the drug achieved a 16% relative risk reduction of cardiovascular death and total heart failure events.

Patients with a single cardiometabolic disease have an approximately 48% greater risk of developing all-cause dementia than those without a cardiometabolic disease.

In a real-world, 6-month analysis, glucagon-like peptide-1 programs with obesity telemedicine behavioral programs resulted in benefits to weight loss and blood pressure.

When compared with adults 45 years and older, those 18 to 44 years are less likely to receive treatment or achieve target goals for cardiometabolic risk factors.

Investigators of a study used a systematic review and meta-analysis to evaluate the risk of major adverse cardiac events related to cannabis by using real-world data.

Investigators find that patients with moderate weight loss or those who were weight resistant still had improvement in cardiometabolic health.

Investigators find that the risk for new-onset diabetes is especially prominent for patients aged 20 to 29 years.

Widaplik is a single pill combination of telmisartan, amlodipine and indapamide used to lower blood pressure in adult patients.

Investigators found that simvastatin added to escitalopram for patients with obesity and major depressive disorder did not have increased antidepressive effects.

The primary challenges include disruption in medication supply and increased demand for essential medications due to heightened health concerns.